A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults
A Randomized, Open-Label, Multi-Arm, Dose Escalation, Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GI-13020; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Hepatitis B Virus X, Surface and Core Antigens, at Various Dose Levels and Regimens in Healthy Adults.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85283
- Celerion
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Signed, written, informed consent from the subject before any study-specific procedures are performed
- Free of obvious health problems as established by medical history and clinical examination before entering into the study
- If female, negative pregnancy test and for women of childbearing potential willingness to use reliable method of birth control during the study and for 30 days after the last dose of study medication
- Male or female aged ≥ 18 years at the time of first dose
- Negative scratch test (immediate hypersensitivity, immunoglobulin E (IgE) mediated) to S. cerevisiae
Exclusion Criteria:
- Hospitalization in the last 6 months
- No medicine adjustments in the last 6 months
- History of anaphylaxis from any cause
- History of hepatitis B virus (HBV) infection as evidenced by detection of HBV Surface and Core antigens
- History of vaccination with HBV prophylactic vaccine or positive for antibody to HBV Surface and Core antigens
- Known exposure to HBV within the past 6 weeks
- Increased alpha fetoprotein (AFP) at screening
- History of hepatitis C virus (HCV) infection or positive HCV antibody, Herpes zoster, shingles or any other chronic viral infection
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests
- Known history of HIV infection or positive HIV antibody test at screening
- History of demyelinating disease such as Guillain-Barre Syndrome
- History of Bell's Palsy
- Immunosuppression as a result of underlying illness or treatment
- History of cancer within the last 5 years with the exception of localized basal or squamous cell carcinoma or Stage 1A cervical cancer
- History of Crohn's disease or ulcerative colitis
- History of autoimmune disease
- History of organ transplantation
- Concurrent and chronic therapy with immunosuppressive drugs including systemic corticosteroids
- Receipt of investigational drugs or vaccines within 30 days or 5 half lives, whichever is longer, prior to first injection with the study drug
- Receipt of immunoglobulin or other blood products within 3 months prior to enrollment
- Receipt of allergy shots within the preceding 7 days or expected to receive allergy shots during the study and 7 days following completion of study
- Receipt of biologics
- Negative histamine response on scratch test at screening
- High risk for noncompliance with the protocol
- Alcohol and/or IV drug abuse within the past year
- Positive urine drug test at screen visit
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: GS-4774 at 10 yeast units (YU)
10 YU of GS-4774 given either weekly or monthly
|
GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens.
The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
Autres noms:
|
|
Expérimental: GS-4774 at 40 YU
40 YU of GS-4774 given either weekly or monthly
|
GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens.
The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
Autres noms:
|
|
Expérimental: GS-4774 at 80YU
80 YU of GS-4774 given either weekly or monthly
|
GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens.
The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety of GS-4774 at various doses
Délai: 6 months
|
Frequency of serious adverse events Frequency and severity of common non-serious adverse events Frequency of discontinuations of therapy due to adverse events Common laboratory assessments (chemistry, hematology, urinalysis) Dose Limiting Toxicities
|
6 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Immunogenicity of various doses and dosing regimens of GS-4774
Délai: 6 months
|
Frequency and magnitude of antigen specific immune responses by enzyme-linked immunosorbent spot (ELISpot) assay for cytokine production, to include interferon gamma (IFNγ) Frequency and magnitude of antigen specific immune responses by lymphocyte proliferation assay (LPA) Frequency and magnitude of anti-Saccharomyces cerevisiae antibody (ASCA) responses Pentamer staining for HBV specific T cells Frequency of regulatory T cells (Treg) responses
|
6 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- GI-13020-01
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .